Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +67.3%
S&P 500 total return (same window) +37.0%
Excess return +30.3%

Annualized: +51.0% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 99.0% · Options excluded: 0.0%

Sector breakdown

04
Healthcare 100.0%

Full portfolio 3 positions

05
Type Streak 8Q trend
BCAX Bicara Therapeutics Inc. - Common Stock $93,924,820 63.77% 3,163,517 $30,863,396 Down ×1
CBLL CeriBell, Inc. - Common Stock $42,900,106 29.13% 2,205,661 $2,470,340
CTNM Contineum Therapeutics, Inc. - Common stock $10,459,410 7.10% 638,158 $2,125,067

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
BCAX Trimmed -7K +$30.9M
CBLL Price move only +0 +$2.5M
CTNM Price move only +0 +$2.1M

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
CRGX June 30, 2025 1,100,732 $4,479,979 No longer tracked